Wilex Revenue and Competitors
Estimated Revenue & Valuation
- Wilex's estimated annual revenue is currently $6.7M per year.
- Wilex's estimated revenue per employee is $141,809
Employee Data
- Wilex has 47 Employees.
- Wilex grew their employee count by 34% last year.
Wilex's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & Sprecher des Vorstands at Heidelberg Pharma AG | Reveal Email/Phone |
2 | Chief Business Officer | Reveal Email/Phone |
3 | Head Business Applications | Reveal Email/Phone |
4 | VP Human Resources | Reveal Email/Phone |
5 | VP Medical | Reveal Email/Phone |
6 | Associate Director Pharmacology and Toxicology | Reveal Email/Phone |
7 | Associate Director In Vivo Biology | Reveal Email/Phone |
8 | Director Regulatory Affairs | Reveal Email/Phone |
9 | Associate Director In vitro Biology | Reveal Email/Phone |
10 | Director, Project & Portfolio Management | Reveal Email/Phone |
Wilex Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 15 | -32% | N/A | N/A |
#10 | $10.1M | 48 | -9% | N/A | N/A |
What Is Wilex?
Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company's own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Former clinical assets MESUPRON® and REDECTANE® have been partnered. Our mission is to research and develop therapies for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.
keywords:N/A
N/A
Total Funding
47
Number of Employees
$6.7M
Revenue (est)
34%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Wilex News
Tracon Pharmaceuticals; Wilex. is one of the market's manufacturers. Regional studies like. North America (United States, Canada and Mexico); Europe (...